The Formidable Challenge of Controlling High Mannose-Type N-Glycans in Therapeutic mAbs

Time: 1:50 pm
day: Track C - Day 1 PM


  • Glycosylation is a critical quality attribute for mAbs because their clinical efficacy and safety are significantly affected by their glycosylation profile
  • As opposed to endogenous IgGs, marketed therapeutic mAbs contain higher levels of high mannose glycans, which can affect efficacy, pharmacokinetics, and stability
  • Discussing how current trends in biopharmaceutical manufacturing, such as process intensification and the rise of biosimilars, emphasise the need for a thorough understanding of the cellular processes, as well as the biotechnical process aspects that govern the production of high mannose-type N-glycans, in order to establish robust manufacturing processes